MediSieve reaches finals of Medtech Insight Awards | Innovation

Medical device company MediSieve has made it into the finals of a competition designed to recognise the organisations devoted to improving human lives.

MediSieve has been announced as a finalist in the Medtech Awards for the Innovative Team of the Year category.

The company has developed magnetic blood filtration technology which could be used to treat malaria and other blood-borne diseases such as sepsis and leukaemia. MediSieve’s technology targets specific components in certain blood-borne diseases and removes them from the patient’s bloodstream.

This year, the Medtech Insights Awards is aiming to highlight the work and being done across the medical device and diagnostics industries. The feature categories such as technological innovations, personal accomplishments and emerging markets.

Dr George Frodsham, founder and CEO of MediSieve, spoke about the company’s technology, saying: “This has the potential to revolutionise the treatment of a huge variety of blood-borne diseases. Our development of the technology focused on a rapid, highly efficient, biocompatible magnetic filter that can safely capture magnetic components from blood flowing through an extra-corporeal loop.”“It’s an honour to be shortlisted alongside some of the world’s most innovative companies,” Dr Frodsham continued. “And it’s a great platform to raise awareness of the benefits and developments of MediSieve. In the past year-and-a-half, we have solved some big technical challenges, from getting the filter through pre-clinical testing, to generating enough data to win a grant from the NIHR to perform first-in-man clinical trials, to securing £1.75M of funding from investors! This was a feat considering we were only a team of four with very limited resources.”

The Medtech Insights Awards are organised in partnership with the MedTech Conference in Philadelphia. The winners will be announced on Sunday 23 September

You might also like More from author

Leave A Reply

Your email address will not be published.